Vista Pharmaceuticals Ltd.

As of March 31, 2026, Vista Pharmaceuticals Ltd. carries a market capitalization of 376.08M, placing it among publicly traded companies globally. Its enterprise value stands at 474.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Vista Pharmaceuticals Ltd. has 61.55M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 6.83, and the price-to-book ratio stands at 1.03.

These figures are as of March 31, 2026. The EV/Sales ratio of 8.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 474.88M versus a market cap of 376.08M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Vista Pharmaceuticals Ltd. maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.41, indicating elevated leverage, while an interest coverage ratio of -13.28 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Vista Pharmaceuticals Ltd. posted a negative return on equity (ROE) of -29.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.91, reflecting losses generated across the asset base. The company generates approximately 1.80M in revenue per employee across its workforce of 30.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.54 indicates how many times Vista Pharmaceuticals Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Vista Pharmaceuticals Ltd. recorded an income tax benefit of -40.90M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -161.51M and -120.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vista Pharmaceuticals Ltd.'s stock has declined approximately 44.70% over the past 52 weeks. The 50-day moving average sits at 6.21, while the 200-day moving average is 7.09.

Over the twelve months ended March 31, 2026, Vista Pharmaceuticals Ltd. generated 54.00M in revenue and converted that into -120.61M in net income, yielding earnings per share of -2.00. EBITDA reached -146.16M, while operating income came in at -153.65M.

As of March 31, 2026, Vista Pharmaceuticals Ltd. holds 1.07M in cash and equivalents against 99.87M in total debt, resulting in a net debt position of 98.80M. Total book value stands at 364.41M, with working capital of -12.83M providing operational flexibility.

Over the twelve months ended March 31, 2026, Vista Pharmaceuticals Ltd. posted a gross margin of 3.29, reflecting its pricing power and cost economics. The operating margin of -284.57 and net profit margin of -223.38 provide insight into operational efficiency.

Vista Pharmaceuticals Ltd.'s most recent stock split took place on June 25, 2015 with a 50:83 split ratio.